Bonjour,
Je reprends un post d'un membre de Boursorama posté ce jour que je vais approfondir tout en résumant son composé:
The TREAT-NMD Advisory Committee for Therapeutics (TACT) reviewed three applications at the 10th TACT review meeting which took place in October in Chicago, USA:
- Seth Porter, FibroGen Inc, San Francisco, USA: Clinical trial of FG-3019 in patients with Duchenne muscular dystrophy
- Gloria Vigliani: Naproxcinod for the treatment of Duchenne muscular dystrophy
- Suyash Prasad, Audentes Therapeutics Inc, San Francisco, USA: Systemically delivered AAV8 gene therapy for X-linked myotubular myopathy (XLMTM)
Confidential reports have been sent to the applicants and the non-confidential summaries are now available on the TREAT-NMD website.
TACT would once again like to thank Parent Project Muscular Dystrophy, Cure Duchenne and Myotubular Trust for co-sponsoring this meeting.
The Chair and Secretariat have been reviewing applications for the 11th TACT review meeting which will be taking place in Dublin, Ireland between 28-29 March 2015. Further details will be available in the next TREAT-NMD newsletter.
Looking forward, the 12th TACT review meeting will take place between 4-6 December 2015 in Washington DC (USA). Anyone wishing to submit a proposal this meeting should contact the TACT secretariat via louise.johnston@ncl.ac.uk as soon as possible or visit the TACT section of the website for more details of the application process
lien daté du 31 janvier 2015
http://www.treat-nmd.eu/newsletter/index.php?ezine_id=121
il faut aller à la onzième ligne
http://www.treat-nmd.eu/resources/tact/reviews/past/
*On y apprend que le naproxcinod (repris par une société/partenaire non divulgué)
http://www.treat-nmd.eu/resources/tact/reviews/past/Naproxcinod-hct3012-DMD/
*ainsi que Clinical Trial of FG-3019
http://www.treat-nmd.eu/resources/tact/reviews/past/fg-3019/
Ont tous deux demandé un rapport d'efficacité dans la DMD de leur produit respectif durant donc la 10e séance de révision TACT qui a eu lieu en octobre 2014 à Chicago, USA.
Les rapports détaillés ont été envoyés aux demandeurs....
Donc ma question est ce que le naproxcinod ne risque-il pas de ressortir comme efficace dans la DMD et si oui quel impact cela peut il avoir sur le cours?
Merci d'avance
Bonne soirée